UK Wants Early Access Scheme To Remain ‘Relevant And Attractive’ Following Brexit
Proposals Aim To Reduce Burden Associated With Collecting Real-World Data
The MHRA has drawn up measures to improve regulatory certainty around the UK’s early patient access scheme while reducing regulatory burden in certain areas of its operation.
You may also be interested in...
Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.
The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.
The European Medicines Agency expects its new guideline will improve planning of confirmatory trials that include non-inferiority and therapeutic equivalence comparisons.